Alpha Anomeric
Novel oligonucleotide chemistry platform for inherited genetic diseases
Alpha Anomeric is using a novel, proprietary oligonucleotide chemistry platform for the design of a new class of RNA modulating oligonucleotides. These will be evaluated for the treatment of various inherited genetic diseases.
CEO Wolfgang Renner
Advent Contact Dominic Schmidt